News | December 29, 2021
Translumina to set up Asia's largest heart valve facility at AMTZ Vizag
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
Over the next few years, Philips aims to double the number of its active cath labs in India with a special focus on improving accessibility to quality cardiac and neurovascular care in tier 2 and tier 3 cities
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
_256_384.jpg)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
Subscribe To Our Newsletter & Stay Updated
